A Phase 2 interventional study of PF-06651600 Placebo and PF-06651600 in Crohn's Disease, sponsored by Pfizer. Completed at 195 sites in 26 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-30.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Crohn Disease by Pfizer — none open to participants now, none under way, none of them phase 3. Crohn Disease · Pfizer.
Among the 17 studies in Crohn Disease by Pfizer, this one is the 4th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2018, is one of 9 in phase 2, and was the 13th registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →None of the 17 studies in Crohn Disease by Pfizer is open now. The open studies under Crohn Disease, anywhere →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 1
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 244 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 180 across the 11 interventional studies, 1,431 across the 5 observational. Of the 17 that completed or were terminated, 14 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Crohn Disease by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 weeks) dosed once daily and PF-06700841 (60 mg for 12 weeks) dosed once daily during an induction period of 12 weeks, followed by an open label extension period at doses of 50 mg and 30 mg of PF 06651600 and PF 06700841, respectively, for 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must have inadequate response to, loss of response to, or intolerance to at least one conventional therapy for CD:
•; (azathioprine [AZA], 6 MP, or methotrexate [MTX]); Anti TNF inhibitors (infliximab, adalimumab,certolizumab); Anti integrin inhibitors (eg, vedolizumab); Anti IL 12/23 inhibitor (ustekinumab).
Subjects currently receiving the following treatment for CD are eligible providing they have been on stable doses as described below:
Exclusion Criteria:
Subjects receiving the following therapies within the time period described below or expected to receive any of these therapies during the study period:
Anti TNF inhibitors (or biosimilars thereof) as described below:
Other procedures(s) or product(s), such as immunosuppressants used in transplantation (eg, mycophenolate mofetil, cyclosporine, rapamycin, or tacrolimus) or live (attenuated) vaccine within 30 days prior to baseline.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo PF-06700841 · Drug: PF-06700841
Drug: PF-06651600 Placebo · Drug: PF-06651600
12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period
SES CD50 was defined as 50% improvement from baseline in SES-CD. Baseline was defined as last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
Time frame: Week 12
Number of Participants With Laboratory Test Abnormalities During OLE Period
Pre-specified criteria for lab abnormalities included- hematology: hemoglobin(Hb), erythrocytes (ery),hematocrit:\<0.8\*lower limit of normal(LLN);reticulocytes: \<0.5\*LLN, \>1.5\*upper limit of normal(ULN); ery mean corpuscular(EMC) volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN,\>1.5\*ULN;lymphocyte,neutrophil(10\^9/L):\<0.8\*LLN,\>1.2\*ULN;basophil,eosinophil,monocyte(10\^9/L):\>1.2\*ULN;activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8;urine,glucose,protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants According to Categorization of Vital Signs During OLE Period
Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (millimeter of mercury \[mmHg\]), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and change \>= 30 (mmHg) decrease; PR: value \> 120 (beats per minute \[bpm\]).
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period
Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc \>=480 milli second (msec) or an absolute change in QTc greater than (\>) 60 msec. Clinically significant ECG findings were determined by the investigator.
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period
An adverse event (AE) was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period
A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants With Discontinuations Due to Adverse Events During OLE Period
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.
Time frame: From start of study intervention in OLE period up to 4 weeks after last dose of study intervention (up to 56 weeks)
Number of Participants With Laboratory Test Abnormalities During Induction Period
Pre-specified criteria for lab abnormalities included- hematology: hemoglobin, erythrocytes, hematocrit:\<0.8\*LLN; reticulocytes: \<0.5\*LLN, \>1.5\*ULN; EMC volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN, \>1.5\*ULN; lymphocyte, neutrophil(10\^9/L):\<0.8\*LLN, \>1.2\*ULN; basophil, eosinophil, monocyte(10\^9/L):\>1.2\*ULN; activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8; urine, glucose, protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants According to Categorization of Vital Signs During Induction Period
Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (mmHg), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and PR: value \> 120 (bpm).
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period
Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc greater than or equal to (\>=)480 milli second (msec) or an absolute change in QTc greater than (\>)60 msec. Clinically significant ECG findings were determined by the investigator.
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period
A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants Discontinuation Due to Adverse Events During Induction Period
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.
Time frame: From start of study intervention on Day 1 up to Week 12
Number of Participants With Serious Infections During Induction Period
Participants were monitored for development of any infection (viral, bacterial and fungal). Serious infections were treated infections that required parenteral antimicrobial therapy and were present with positive pre-treatment culture and required hospitalization for treatment/met other criteria that required the infection to be classified as SAE. An SAE was any untoward medical occurrence at any dose that: resulted in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity/results in congenital anomaly/birth defect. Treated infections were infections that required antimicrobial therapy by any route of administration/required any surgical intervention (e.g., incision and drainage).
Time frame: From start of study intervention on Day 1 up to Week 12
Percentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period
CMEI was defined as reduction of \>=3 points from baseline in SES-CD score as assessed by centrally read SES-CD score. Baseline: last measurement prior to first dosing on Day1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for 4 domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5cm),2=Large ulcer(0.5-2cm),3=very large ulcer(\>2cm); ulcerated surface score: 0=none,1=\<10%,2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
Time frame: Week 12
Mean Change From Baseline in SES-CD Score at Week 12: Induction Period
Mean change from baseline in SES-CD score at Week 12 analyzed using analysis of covariance(ANCOVA)model with treatment,baseline disease activity/extent as factors, baseline SES CD score as covariate. Baseline=last measurement prior to first dosing on Day 1. Following bowel segments used for calculating SES-CD scores: Ileum,right C,transverse C,left C,rectum. Each segment assessed for four domains:presence of ulcers, ulcerated surface, affected surface,presence of narrowing, each score on a scale of 0-3,higher scores=more severe condition. Presence of ulcers score:0=none,1=small ulcer:(0.1-0.5cm),2=large ulcer(0.5-2cm),3=very large ulcer(\>2 cm);ulcerated surface score:0=none,1=\<10%,2=10-30%,3=\>30%;affected surface score:0=unaffected segment,1=\<50%, 2=50-75%,3=\>75%;presence of narrowing score:0=none,1=single,can be passed,2=multiple can be passed,3=cannot be passed. Total SES CD score=sum of each domain score for all 5 bowel segments,range from 0 to 60,higher score =more severe disease.
Time frame: Baseline and Week 12
Percentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period
SES CD25 was defined as \>=25% improvement from baseline in SES CD. Baseline was defined as the last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period
Endoscopic remission was defined as SES-CD score of \<= 2. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
Time frame: Week 12
Percentage of Participants Achieving Mucosal Healing at Week 12: Induction Period
Mucosal healing was defined as complete absence of ulcers.
Time frame: Week 12
Percentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period
CMEI was defined as reduction of \>=3 points from baseline as assessed by centrally read SES CD score. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5 cm),2=Large ulcer(0.5-2 cm),3=very large ulcer(\>2 cm); ulcerated surface score: 0=none,1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0-60, higher score indicating more severe disease.
Time frame: Week 64 (Week 52 of OLE period)
Percentage of Participants Achieving SES CD 25 and SES CD 50 at Week 64 Among Participants Who Achieved SES CD 25 and SES CD 50 at Week 12 (Baseline of OLE Period): OLE Period
SES CD50 and SES CD25: 50% and 25% improvement from baseline, respectively. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 cm), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
Time frame: Week 64 (Week 52 of OLE period)
The study consisted of a 12-weeks induction period and a 52-weeks open label extension (OLE) period. The participants who completed induction period, entered the 52-week OLE period.
| Milestone | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|---|---|---|
| Started | 79 | 93 | 72 | 0 | 0 | 0 | 0 |
| Completed | 68 | 84 | 65 | 0 | 0 | 0 | 0 |
| Not completed | 11 | 9 | 7 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 6 | 4 | 4 | 0 | 0 | 0 | 0 |
| Withdrew: No longer meets eligibility criteria | 0 | 2 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 36 | 84 | 32 | 64 |
| Completed | 0 | 0 | 0 | 20 | 45 | 21 | 34 |
| Not completed | 0 | 0 | 0 | 16 | 39 | 11 | 30 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 5 | 11 | 3 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 3 | 11 | 3 | 8 |
| Withdrew: No longer met eligibility criteria | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 7 | 13 | 4 | 15 |
SES CD50 was defined as 50% improvement from baseline in SES-CD. Baseline was defined as last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
| Percentage of participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction in Simple Endoscopic Score for Crohn's Disease (SES CD50) at Week 12: Induction Period | 12.8 (7.1 to 19.9) | 27.2 (19.6 to 35.7) | 33.8 (25.1 to 43.1) |
Pre-specified criteria for lab abnormalities included- hematology: hemoglobin(Hb), erythrocytes (ery),hematocrit:\<0.8\*lower limit of normal(LLN);reticulocytes: \<0.5\*LLN, \>1.5\*upper limit of normal(ULN); ery mean corpuscular(EMC) volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN,\>1.5\*ULN;lymphocyte,neutrophil(10\^9/L):\<0.8\*LLN,\>1.2\*ULN;basophil,eosinophil,monocyte(10\^9/L):\>1.2\*ULN;activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8;urine,glucose,protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities During OLE Period | 33 | 76 | 26 | 56 |
Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (millimeter of mercury \[mmHg\]), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and change \>= 30 (mmHg) decrease; PR: value \> 120 (beats per minute \[bpm\]).
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| DBP; value < 50 (mmHg) | 0 | 2 | 0 | 1 |
| DBP; change >=20 (mmHg) increase | 4 | 6 | 2 | 6 |
| DBP; change >=20 (mmHg) decrease | 1 | 4 | 3 | 8 |
| PR; value > 120 (bpm) | 0 | 1 | 0 | 0 |
| SBP; value < 90 (mmHg) | 0 | 2 | 0 | 1 |
| SBP; change >= 30 (mmHg) increase | 1 | 2 | 0 | 5 |
| SBP; change >= 30 (mmHg) decrease | 3 | 0 | 3 | 2 |
Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc \>=480 milli second (msec) or an absolute change in QTc greater than (\>) 60 msec. Clinically significant ECG findings were determined by the investigator.
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During OLE Period | 0 | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) During OLE Period | 32 | 58 | 25 | 54 |
A serious adverse event (SAE) was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During OLE Period | 6 | 10 | 5 | 16 |
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.
| Participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Discontinuation from study due to TEAEs | 0 | 1 | 0 | 0 |
| Permanent discontinuation from any study intervention due to TEAEs | 7 | 13 | 4 | 15 |
Pre-specified criteria for lab abnormalities included- hematology: hemoglobin, erythrocytes, hematocrit:\<0.8\*LLN; reticulocytes: \<0.5\*LLN, \>1.5\*ULN; EMC volume: \<0.9\*ULN, \>1.11\*ULN;EMC Hb: \<0.9\*LLN; platelets:\>1.75\*ULN; leukocytes(10\^9/L): \<0.6\*LLN, \>1.5\*ULN; lymphocyte, neutrophil(10\^9/L):\<0.8\*LLN, \>1.2\*ULN; basophil, eosinophil, monocyte(10\^9/L):\>1.2\*ULN; activated partial thromboplastin time (sec): \>1.1\*ULN. Chemistry: bilirubin(mg/dL),aspartate aminotransferase(AT),alanine AT(units per litre)\>3.0\*ULN; protein, albumin(g/dL):\<0.8\*LLN; creatinine, triglycerides (mg/dL):\>1.3\*ULN; urate(mg/dL):\>1.2\*ULN, potassium (mEq/L):\<0.9\*LLN; calcium (mg/dL): \<0.9\*LLN,\>1.1\*ULN. Urinalysis: pH\>8; urine, glucose, protein(mg/dl); ketones, nitrite, urine Hb(scalar):\>=1. Number of participants with any lab abnormality meeting pre-specified criteria are reported.
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Number of Participants With Laboratory Test Abnormalities During Induction Period | 67 | 72 | 61 |
Vital signs including blood pressure (diastolic blood pressure \[DBP\], systolic blood pressure \[SBP\], and pulse rate \[PR\]) were measured in a supine position using automated devices. DBP included value \< 50 (mmHg), change \>=20 (mmHg) increase and change \>=20 (mmHg) decrease; SBP: value \< 90 (mmHg), change \>= 30 (mmHg) increase and PR: value \> 120 (bpm).
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Diastolic blood pressure; value < 50 (mmHg) | 1 | 0 | 0 |
| Diastolic blood pressure; change >=20 (mmHg) increase | 4 | 2 | 4 |
| Diastolic blood pressure; change >=20 (mmHg) decrease | 4 | 2 | 4 |
| Pulse rate; value > 120 (bpm) | 4 | 1 | 0 |
| Systolic blood pressure; value < 90 (mmHg) | 0 | 3 | 0 |
| Systolic blood pressure; change >= 30 (mmHg) increase | 3 | 2 | 7 |
| Systolic blood pressure; change >= 30 (mmHg) decrease | 0 | 0 | 0 |
Single twelve lead ECGs were obtained using an automated ECG machine after participant had rested quietly for at least 10 minutes in a supine position. QTc prolongations were defined as a QTc greater than or equal to (\>=)480 milli second (msec) or an absolute change in QTc greater than (\>)60 msec. Clinically significant ECG findings were determined by the investigator.
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Number of Participants With Abnormal Clinically Significant Electrocardiogram Findings During Induction Period | 1 | 0 | 0 |
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. An AE was considered TEAE to a given treatment if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) During Induction Period | 51 | 46 | 49 |
A SAE was any untoward medical occurrence at any dose that: resulted in death; was life-threatening (immediate risk of death); required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions) or resulted in congenital anomaly/birth defect or was considered an important medical event. An SAE was considered as TESAE if the event started during the effective duration of treatment regardless of whether a similar event of equal or greater severity existed in the baseline period.
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAE) During Induction Period | 6 | 4 | 4 |
An AE was any untoward medical occurrence in a study participant administered a study intervention; the event need not necessarily have a causal relationship with the treatment or usage. Discontinuations from study due to TEAEs were defined as participants with an AE record indicating the AE caused permanent discontinuation from the study but action taken with study treatment was not drug withdrawn. Permanent discontinuations from any study intervention due to TEAEs were defined as participants with an AE record indicating that action taken with study treatment was drug withdrawn. In this outcome measure number of participants with discontinuation from study due to AEs and permanent discontinuation from study intervention due to AEs are reported.
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Discontinuations from study due to TEAEs | 0 | 1 | 0 |
| Permanent discontinuations from any study intervention due to TEAEs | 6 | 4 | 4 |
Participants were monitored for development of any infection (viral, bacterial and fungal). Serious infections were treated infections that required parenteral antimicrobial therapy and were present with positive pre-treatment culture and required hospitalization for treatment/met other criteria that required the infection to be classified as SAE. An SAE was any untoward medical occurrence at any dose that: resulted in death; is life-threatening; requires inpatient hospitalization/prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity/results in congenital anomaly/birth defect. Treated infections were infections that required antimicrobial therapy by any route of administration/required any surgical intervention (e.g., incision and drainage).
| Participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Number of Participants With Serious Infections During Induction Period | 0 | 1 | 2 |
CMEI was defined as reduction of \>=3 points from baseline in SES-CD score as assessed by centrally read SES-CD score. Baseline: last measurement prior to first dosing on Day1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for 4 domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5cm),2=Large ulcer(0.5-2cm),3=very large ulcer(\>2cm); ulcerated surface score: 0=none,1=\<10%,2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
| Percentage of participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Percentage of Participants Who Achieved Clinically Meaningful Endoscopic Improvement (CMEI) (Reduction of >=3 Points From Baseline in SES-CD Score) at Week 12: Induction Period | 29.5 (21.7 to 38.9) | 42.4 (34.2 to 51.5) | 57.7 (47.6 to 67.2) |
Mean change from baseline in SES-CD score at Week 12 analyzed using analysis of covariance(ANCOVA)model with treatment,baseline disease activity/extent as factors, baseline SES CD score as covariate. Baseline=last measurement prior to first dosing on Day 1. Following bowel segments used for calculating SES-CD scores: Ileum,right C,transverse C,left C,rectum. Each segment assessed for four domains:presence of ulcers, ulcerated surface, affected surface,presence of narrowing, each score on a scale of 0-3,higher scores=more severe condition. Presence of ulcers score:0=none,1=small ulcer:(0.1-0.5cm),2=large ulcer(0.5-2cm),3=very large ulcer(\>2 cm);ulcerated surface score:0=none,1=\<10%,2=10-30%,3=\>30%;affected surface score:0=unaffected segment,1=\<50%, 2=50-75%,3=\>75%;presence of narrowing score:0=none,1=single,can be passed,2=multiple can be passed,3=cannot be passed. Total SES CD score=sum of each domain score for all 5 bowel segments,range from 0 to 60,higher score =more severe disease.
| Units on a scale | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Mean Change From Baseline in SES-CD Score at Week 12: Induction Period | -0.1 (-1.32 to 1.12) | -3.1 (-4.22 to -2.02) | -5.0 (-6.36 to -3.72) |
SES CD25 was defined as \>=25% improvement from baseline in SES CD. Baseline was defined as the last measurement prior to first dosing on Day 1. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
| Percentage of participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving >=25% Reduction in SES-CD From Baseline (SES-CD 25) at Week 12: Induction Period | 25.6 (17.7 to 34.3) | 39.1 (30.6 to 47.4) | 56.3 (46.2 to 66.4) |
Endoscopic remission was defined as SES-CD score of \<= 2. Following bowel segments were used for calculating SES-CD scores: Ileum, right colon(C), transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 centimeter\[cm\]), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
| Percentage of participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Remission (SES-CD Score of <= 2) at Week 12: Induction Period | 5.1 (2.3 to 11.2) | 7.6 (4.0 to 13.2) | 12.7 (7.2 to 20.8) |
Mucosal healing was defined as complete absence of ulcers.
| Percentage of participants | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD |
|---|---|---|---|
| Percentage of Participants Achieving Mucosal Healing at Week 12: Induction Period | 5.1 (2.3 to 11.2) | 10.9 (6.1 to 17.7) | 16.9 (10.1 to 25.8) |
CMEI was defined as reduction of \>=3 points from baseline as assessed by centrally read SES CD score. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on scale of 0-3, higher scores indicated more severe condition. Presence of ulcers score: 0=none,1=small ulcer: (0.1-0.5 cm),2=Large ulcer(0.5-2 cm),3=very large ulcer(\>2 cm); ulcerated surface score: 0=none,1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0-60, higher score indicating more severe disease.
| Percentage of participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| Percentage of Participants Achieving CMEI at Week 64 Among Participants Who Achieved CMEI Response at Week 12 (Baseline of OLE Period): OLE Period | 27.3 (10.5 to 56.4) | 44.1 (30.7 to 59.5) | 54.5 (30.2 to 80.0) | 42.1 (28.5 to 56.7) |
SES CD50 and SES CD25: 50% and 25% improvement from baseline, respectively. Baseline: last measurement prior to first dosing on Day 1 of Week 12. Following bowel segments were used for calculating SES-CD scores: Ileum, right C, transverse C, left C and rectum. Each segment assessed for four domains: presence of ulcers, ulcerated surface, affected surface and presence of narrowing, each scored on a scale of 0 to 3, higher scores indicated more severe condition. Presence of ulcers score: 0=none, 1=small ulcer: (0.1-0.5 cm), 2=Large ulcer(0.5-2 cm), 3=very large ulcer(\>2 cm); ulcerated surface score: 0=none, 1=\<10%, 2=10-30% and 3=\>30%; affected surface score: 0=unaffected segment, 1=\<50%, 2=50-75% and 3=\>75%; presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed and 3=cannot be passed. Total SES CD score was determined by sum of each domain score for all 5 bowel segments and ranged from 0 to 60, higher score indicating more severe disease.
| Percentage of participants | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|
| SES-CD 25 | 25.0 (6.9 to 58.2) | 41.9 (26.9 to 57.9) | 54.5 (30.2 to 80.0) | 42.1 (28.5 to 56.7) |
| SES-CD 50 | 25.0 (2.6 to 68.0) | 36.4 (19.6 to 55.6) | 50.0 (20.1 to 79.9) | 36.4 (19.6 to 55.6) |
Collected over Induction Period: From start of study intervention on Day 1 up to Week 12 (for a maximum duration of 12 weeks); OLE Period: From start of study intervention in OLE period (Week 12) up to 4 weeks after last dose of study intervention on Week 64 (for a maximum duration of 56 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Induction Period: Placebo QD | 0/79 (0%) | 6/79 (7.6%) | 20/79 (25.3%) |
| Induction Period: Ritlecitinib 200 mg/50 mg QD | 0/93 (0%) | 4/93 (4.3%) | 20/93 (21.5%) |
| Induction Period: Brepocitinib 60 mg QD | 0/72 (0%) | 4/72 (5.6%) | 17/72 (23.6%) |
| OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | 0/36 (0%) | 6/36 (16.7%) | 29/36 (80.6%) |
| OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | 0/84 (0%) | 10/84 (11.9%) | 34/84 (40.5%) |
| OLE Period: Placebo QD -> Brepocitinib 30 mg QD | 0/32 (0%) | 5/32 (15.6%) | 19/32 (59.4%) |
| OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD | 0/64 (0%) | 16/64 (25%) | 31/64 (48.4%) |
| Event | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 5/79 | 2/93 | 0/72 | 3/36 | 5/84 | 3/32 | 7/64 |
| Humerus fractureInjury, poisoning and procedural complications | 0/79 | 0/93 | 0/72 | 0/36 | 0/84 | 1/32 | 0/64 |
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/79 | 0/93 | 0/72 | 0/36 | 0/84 | 1/32 | 0/64 |
| AnaemiaBlood and lymphatic system disorders | 1/79 | 0/93 | 0/72 | 1/36 | 0/84 | 0/32 | 0/64 |
| Abdominal painGastrointestinal disorders | 0/79 | 0/93 | 0/72 | 1/36 | 0/84 | 0/32 | 1/64 |
| DiarrhoeaGastrointestinal disorders | 0/79 | 0/93 | 0/72 | 1/36 | 0/84 | 0/32 | 0/64 |
| Clostridium difficile colitisInfections and infestations | 0/79 | 0/93 | 0/72 | 1/36 | 0/84 | 0/32 | 0/64 |
| Mesenteric abscessInfections and infestations | 0/79 | 0/93 | 0/72 | 1/36 | 0/84 | 0/32 | 0/64 |
| Acute myocardial infarctionCardiac disorders | 0/79 | 0/93 | 0/72 | 0/36 | 0/84 | 0/32 | 1/64 |
| ConstipationGastrointestinal disorders | 0/79 | 0/93 | 0/72 | 0/36 | 0/84 | 0/32 | 1/64 |
| Event | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | OLE Period: Placebo QD -> Ritlecitinib 50 mg QD | OLE Period: Ritlecitinib 200 mg/50 mg QD -> Ritlecitinib 50 mg QD | OLE Period: Placebo QD -> Brepocitinib 30 mg QD | OLE Period: Brepocitinib 60 mg QD -> Brepocitinib 30 mg QD |
|---|---|---|---|---|---|---|---|
| SARS-CoV-2 test positiveInvestigations | 3/79 | 6/93 | 1/72 | 6/36 | 4/84 | 4/32 | 8/64 |
| Abdominal painGastrointestinal disorders | 1/79 | 2/93 | 4/72 | 4/36 | 5/84 | 4/32 | 6/64 |
| Crohn's diseaseGastrointestinal disorders | 4/79 | 2/93 | 2/72 | 4/36 | 9/84 | 2/32 | 4/64 |
| InsomniaPsychiatric disorders | 0/79 | 0/93 | 0/72 | 4/36 | 0/84 | 1/32 | 0/64 |
| AcneSkin and subcutaneous tissue disorders | 0/79 | 1/93 | 4/72 | 4/36 | 1/84 | 1/32 | 2/64 |
| AnaemiaBlood and lymphatic system disorders | 0/79 | 0/93 | 0/72 | 3/36 | 0/84 | 2/32 | 2/64 |
| TinnitusEar and labyrinth disorders | 0/79 | 0/93 | 0/72 | 3/36 | 1/84 | 0/32 | 0/64 |
| FatigueGeneral disorders | 0/79 | 0/93 | 0/72 | 3/36 | 2/84 | 1/32 | 0/64 |
| PyrexiaGeneral disorders | 0/79 | 0/93 | 0/72 | 3/36 | 2/84 | 1/32 | 3/64 |
| GastroenteritisInfections and infestations | 0/79 | 0/93 | 0/72 | 3/36 | 0/84 | 0/32 | 1/64 |
The full analysis set (FAS) included all randomized participants who received at least one dose of the randomized investigational drug (ritlecitinib, brepocitinib, or placebo). Participants who received placebo in induction period were analyzed as a single reporting group.
| Age, Continuous(Years) | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | Total |
|---|---|---|---|---|
| Mean | 36.1 ± 13.03 | 34.6 ± 10.64 | 36.5 ± 12.70 | 35.6 ± 12.05 |
| Sex: Female, Male(Participants) | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | Total |
|---|---|---|---|---|
| Female | 37 | 41 | 29 | 107 |
| Male | 42 | 52 | 43 | 137 |
| Ethnicity (NIH/OMB)(Participants) | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 1 | 4 |
| Not Hispanic or Latino | 75 | 91 | 69 | 235 |
| Unknown or Not Reported | 2 | 1 | 2 | 5 |
| Race (NIH/OMB)(Participants) | Induction Period: Placebo QD | Induction Period: Ritlecitinib 200 mg/50 mg QD | Induction Period: Brepocitinib 60 mg QD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 5 | 6 | 7 | 18 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 2 |
| White | 71 | 84 | 61 | 216 |
| More than one race | 1 | 1 | 1 | 3 |
| Unknown or Not Reported | 2 | 2 | 1 | 5 |
Showing the first 100 of 195 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2018 to primary completion in Oct 2023, 68 months.
Results were first posted in Oct 2024, 1 year after primary completion.
Of 56 industry-sponsored phase 2 interventional studies under Crohn Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 68 months is above that.
Counting every sponsor, half of 83 studies reached it within 34 months; a quarter within 23 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: PF-06651600 · PF-06700841